Australia’s research strength is not in doubt. Its next challenge is to build a development system equal to it.
Australia’s cancer science is internationally strong. The harder task is deciding which discoveries are ready for development, generating evidence that reduces the right risks, and building enough capability around the strongest programs for medicines and global oncology companies to emerge.
Cancer Australia describes Australia as a world leader in cancer research.
The new National Health and Medical Research Strategy, covering 2026 to 2036, seeks a sustainable pipeline from discovery through translation and commercialisation.
Oncology could become a test case for that ambition.
Between a scientific discovery and a medicine lie very different decisions: whether the biology is reproducible, which patients should be treated, what a first clinical trial should test, what regulators will require and whether the treatment will still be relevant when it reaches patients.
Australia’s challenge is therefore not merely to commercialise more research. It is to make those development decisions early and well.
Commercialisation is too broad
The Australian government’s medical science investment plan points to a structural weakness: pharmaceutical and biotechnology intellectual property often leaves Australia before early clinical development, taking economic value and opportunities to build local capability with it.
Capital is part of that story, but not the whole story.
Related
A compelling target may lack a practical patient-selection strategy. A promising mechanism may require a trial design or manufacturing approach that makes development unrealistic. The earlier these risks are recognised, the more intelligently scarce research and investment capital can be deployed.
Telix Pharmaceuticals, headquartered in Melbourne and operating internationally, demonstrates that an Australian oncology company can achieve genuine global reach.
The policy question is how Australia makes that outcome less exceptional.
Ask development questions sooner
Before a promising oncology program is described as “commercialisation ready”, it should undergo a structured development-readiness assessment that goes beyond asking whether the science is novel or the intellectual property protectable.
Who are the intended patients? What evidence would justify exposing them to the treatment? What will standard care probably look like when clinical testing begins? What result would make the program no longer worth pursuing? Are manufacturing and regulatory requirements understood early enough to influence research priorities?
Once a research program is being advanced because it may become a cancer medicine, development logic should help determine what evidence should be generated next.
This does not mean making universities behave like drug companies. Basic and curiosity-driven research must remain fundamental. It means applying a different standard once therapeutic development becomes an explicit objective.
Reward evidence, not optimism
A strong development system should reward evidence that improves decisions, not simply continued positive results. For some programs, the most valuable experiment may be the one that demonstrates early that the therapeutic hypothesis is unlikely to survive clinical development.
Stopping such a program is not necessarily failure. It can prevent years of spending and allow capital, talent and laboratory effort to move to stronger opportunities.
Funding milestones could therefore place greater weight on evidence that resolves development uncertainties, including patient selection, clinical feasibility, manufacturing and differentiation from future standards of care.
Build a national review mechanism
The NHMRC Research Translation Strategy for 2026 to 2030 already aims to strengthen translation by expanding funding pathways, developing capability and deepening collaboration across the research system.
Australia could take that direction further in oncology without creating another funding agency.
A national oncology development review mechanism could bring experienced clinical developers, translational scientists, oncologists, regulatory and manufacturing experts, biotechnology leaders and investors together to review selected programs at defined development points.
Its purpose would be to identify the questions that must be answered before more capital is committed and determine whether the next milestone genuinely reduces development risk.
For stronger programs, that could create a clearer path into clinical development, partnerships and company formation. For weaker ones, it could identify decisive problems before years and millions of dollars are consumed.
Measure what happens after discovery
Australia should judge its biomedical innovation system by what happens after excellent science is produced: whether more oncology programs reach human testing with credible development strategies, whether development expertise deepens locally, whether companies can advance successive programs, and whether Australian discoveries reach global patients through organisations with substantial development activity based here.
The objective is not to keep every discovery or company in Australia. Biomedical innovation is inherently global. It is to make Australia a place where more of the difficult work between discovery and global medicine development can actually be done.
Australia’s research strength is not in doubt. Its next challenge is to build a development system equal to it.
If that middle part of the journey becomes a national capability rather than an occasional success, more Australian cancer discoveries will have a credible chance of becoming medicines and more Australian oncology companies will have a credible chance of becoming global.
Professor David Adler is chief scientific and medical officer of the PATHORA Institute of Pathology & Tissue Medicine. He is a senior pharmaceutical leader in oncology drug development and translational medicine with over 15 years of experience, including a decade in senior leadership at Bayer AG’s Global Oncology Clinical Development organisation. He holds academic appointments at the Hebrew University of Jerusalem, Ben-Gurion University of the Negev, and the University of Bonn.